Skip to main content

Press Releases and Ad-hoc Announcements

21 November 2017	AH: Heidelberg Pharma AG raises approximately EUR 34.4 million from capital measure	PDF
21 November 2017	PM: Heidelberg Pharma AG raises approximately EUR 34.4 million from capital measure	PDF
16 November 2017	AH: Heidelberg Pharma AG announces subscription price for new shares and conversion price for convertible bonds from ongoing capital measure	PDF
13 November 2017	PR: Heidelberg Pharma AG announces results from research collaboration with Heidelberg University and the DKFZ to be presented at ASH Annual Meeting	PDF
03 November 2017	AH: Heidelberg Pharma AG plans capital measure to fund its ATAC development programs	PDF
26 October 2017	Heidelberg Pharma AG: Partner RedHill Announces Orphan Drug Designation for MESUPRON	PDF
19 October 2017	PR: WILEX AG successfully completes change of name to Heidelberg Pharma AG	PDF
09 October 2017	AH: WILEX AG announces adjustment of guidance	PDF
09 October 2017	PR: WILEX AG: Interim management statement for the first nine months of 2017	PDF
26 September 2017	PR: WILEX AG: subsidiary Heidelberg Pharma becomes Runner Up in the category Best New Drug Developer at Annual World ADC Award 2017	PDF
20 September 2017	PR: WILEX AG: Subsidiary Heidelberg Pharma to Present the Proprietary ATAC Technology Platform at the Annual World ADC Summit	PDF
13 July 2017	PR: WILEX reports first half 2017 results	PDF
19 June 2017	PR: WILEX AG: Subsidiary Heidelberg Pharma Signs Exclusive Multi-target Research Agreement with Takeda for the Development of Antibody Targeted Amanitin Conjugates	PDF
19 June 2017	AH: WILEX AG: Subsidiary Heidelberg Pharma Signs Exclusive Multi-target Research Agreement with Takeda for the Development of Antibody Targeted Amanitin Conjugates	PDF
11 May 2017	PR: WILEX AG successfully completes rights issue	PDF
24 April 2017	AH: WILEX AG plans rights issue using authorised capital	PDF
12 April 2017	PR: WILEX AG: Interim management statement on the first three months of 2017	PDF
30 March 2017	PR: WILEX announces financial figures for the 2016 fiscal year and reports on course of business	PDF
06 February 2017	AH: WILEX AG secures financing commitment from its main shareholder dievini	PDF
25 January 2017	PR: WILEX AG: Subsidiary Heidelberg Pharma Exercises Option on BCMA Antibodies of the Max Delbrück Center and Signs License Agreement	PDF
16 January 2017	AH: WILEX Signs Antibody License Agreement with Telix Pharmaceuticals Limited	PDF
16 January 2017	PR: WILEX Signs Antibody License Agreement with Telix Pharmaceuticals Limited	PDF